The information highlighted (if any) are the most recent updates for this brand.
Winrevair, in combination with other pulmonary arterial hypertension (PAH) therapies, is indicated for the treatment of PAH in adult patients with WHO Functional Class (FC) II to III, to improve exercise capacity (see Pharmacology: Pharmacodynamics under Actions).